Aratana Therapeutics Inc (PETX) Receives $8.25 Consensus Target Price from Analysts

Shares of Aratana Therapeutics Inc (NASDAQ:PETX) have received a consensus rating of “Buy” from the eight ratings firms that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $8.25.

A number of research firms have weighed in on PETX. Zacks Investment Research raised Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a report on Saturday, November 10th. TheStreet raised Aratana Therapeutics from a “d” rating to a “c-” rating in a report on Wednesday, November 21st. Stifel Nicolaus decreased their price objective on Aratana Therapeutics from $8.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, August 6th. BidaskClub raised Aratana Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, November 8th. Finally, ValuEngine downgraded Aratana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 8th.

NASDAQ PETX traded down $0.11 during trading on Monday, reaching $6.50. 410,886 shares of the company traded hands, compared to its average volume of 368,256. The company has a current ratio of 3.17, a quick ratio of 2.70 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $321.41 million, a price-to-earnings ratio of -6.70 and a beta of 1.95. Aratana Therapeutics has a 1-year low of $3.67 and a 1-year high of $7.16.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. The company had revenue of $21.56 million for the quarter, compared to the consensus estimate of $5.70 million. Aratana Therapeutics had a negative return on equity of 15.08% and a negative net margin of 52.94%. On average, analysts predict that Aratana Therapeutics will post -0.25 earnings per share for the current year.

In related news, insider Peter Steven St sold 11,513 shares of the business’s stock in a transaction that occurred on Tuesday, October 30th. The shares were sold at an average price of $5.86, for a total value of $67,466.18. Following the completion of the transaction, the insider now owns 562,720 shares in the company, valued at approximately $3,297,539.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ernst Heinen sold 19,308 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The stock was sold at an average price of $6.95, for a total transaction of $134,190.60. Following the completion of the transaction, the insider now owns 135,694 shares of the company’s stock, valued at approximately $943,073.30. The disclosure for this sale can be found here. Insiders sold a total of 106,513 shares of company stock worth $660,966 over the last three months. 5.30% of the stock is owned by company insiders.

Hedge funds have recently bought and sold shares of the stock. American Century Companies Inc. bought a new position in Aratana Therapeutics in the 2nd quarter worth approximately $195,000. MetLife Investment Advisors LLC bought a new stake in shares of Aratana Therapeutics during the 3rd quarter valued at $215,000. Bank of Montreal Can raised its position in shares of Aratana Therapeutics by 152.9% during the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 31,053 shares during the last quarter. Acadian Asset Management LLC bought a new stake in shares of Aratana Therapeutics during the 2nd quarter valued at $487,000. Finally, Northern Trust Corp raised its position in shares of Aratana Therapeutics by 7.2% during the 2nd quarter. Northern Trust Corp now owns 489,766 shares of the biopharmaceutical company’s stock valued at $2,082,000 after acquiring an additional 32,773 shares during the last quarter. Hedge funds and other institutional investors own 64.78% of the company’s stock.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Article: What is a capital gain?

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit